About Akebia therapeutics
Akebia Therapeutics is a fully integrated renal biopharmaceutical company that has been making waves in the industry with its innovative products and cutting-edge research. The company has a late-stage product in global Phase 3 clinical development, which is expected to revolutionize the treatment of renal diseases.
Founded in 2007, Akebia Therapeutics has quickly established itself as a leader in the field of renal medicine. The company's mission is to develop and commercialize novel therapeutics for patients with kidney disease. With a team of experienced scientists and researchers, Akebia Therapeutics is committed to advancing the science of renal medicine and improving patient outcomes.
One of the key strengths of Akebia Therapeutics is its focus on innovation. The company's research efforts are centered around developing new treatments for chronic kidney disease (CKD) and anemia associated with CKD. This focus on innovation has led to several breakthroughs in the field, including the development of vadadustat - a first-in-class oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI).
Vadadustat is currently undergoing global Phase 3 clinical trials for anemia associated with CKD, which affects millions of people worldwide. If successful, vadadustat could become a game-changer in the treatment landscape for this condition.
In addition to its late-stage product pipeline, Akebia Therapeutics also has a commercially available medicine - Auryxia® (ferric citrate). This medication is indicated for controlling serum phosphorus levels in adult patients with CKD on dialysis.
Auryxia® was approved by the US Food and Drug Administration (FDA) in September 2014 and has since been prescribed to thousands of patients across America. Its unique mechanism-of-action makes it an attractive option for healthcare providers looking to manage hyperphosphatemia effectively.
Apart from its innovative products pipeline, Akebia Therapeutics also boasts an impressive track record when it comes to partnerships and collaborations. In recent years, the company has entered into strategic alliances with some leading pharmaceutical companies such as Otsuka Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Corporation among others.
These partnerships have enabled Akebia Therapeutics to leverage their expertise while expanding their reach globally through licensing agreements that allow them access into new markets outside North America where they have already established themselves as leaders within their space
In conclusion, Akebia therapeutics' commitment towards developing novel therapies that address unmet medical needs within Renal Medicine coupled with their strong focus on innovation makes them one of today's most promising biopharmaceutical companies globally.
Their dedication towards improving patient outcomes through cutting-edge research will undoubtedly continue driving growth within this space while providing hope for millions suffering from chronic kidney disease worldwide